Market Risers: Allergy Therapeutics, AstraZeneca, Bunzl

Broker Ratings

Shares of Allergy Therapeutics with EPIC code: LON:AGY has risen 3.55% or 1.25 points during the course of today’s session so far. Investors have stayed positive while the stock has been in play. The high for the period has peaked at 36.5 dipping to 35. The volume total for shares traded up to this point was 284,040 with the average number of shares traded daily being 506,977. The 52 week high is 40.5 about 5.25 points difference from the previous close and the 52 week low at 12.75 is a variance of 22.5 points. Allergy Therapeutics has a 20 SMA of 36.91 and now the 50 day SMA of 36.08. Market capitalisation is now £234.26m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Allergy Therapeutics being recorded at Tuesday, November 2, 2021 at 12:36:28 PM GMT with the stock price trading at 36.5 GBX.

Stock in AstraZeneca found using EPIC: LON:AZN has gained 1.12% or 102 points during the course of today’s session so far. Investors have stayed positive while the stock has been in play. The period high has peaked at 9275 meanwhile the session low reached 9157.81. Volume total for shares traded at this point reached 308,872 whilst the daily average number of shares exchanged is just 1,901,970. The 52 week high for the shares is 9275 some 137 points different to the previous business close and a 52 week low sitting at 6736 a difference of some 2402 points. AstraZeneca now has a 20 SMA at 8962.84 and now the 50 day moving average now at 8747.35. This puts the market capitalisation now at £144,185.74m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Tuesday, November 2, 2021 at 12:35:26 PM GMT with the stock price trading at 9240 GBX.

Stock in Bunzl with EPIC code: LON:BNZL has risen 1.33% or 36 points throughout today’s trading session so far. Buyers have remained optimistic throughout the session. Range high for the period so far is 2745 and a low of 2690. Volume total for shares traded at this point reached 228,634 with the daily average at 699,886. The 52 week high price for the shares is 2745 about 43 points in difference to the previous days close of business and a 52 week low sitting at 2122 making a difference of 580 points. Bunzl now has a 20 SMA at 2552.61 and now a 50 day MA at 2570.22. This puts the market capitalisation now at £9,260.41m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Bunzl being recorded at Tuesday, November 2, 2021 at 12:31:23 PM GMT with the stock price trading at 2738 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival.

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options.

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 trials.

FDA approves AstraZeneca’s Saphnelo Pen for self-administration in SLE

AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative to IV infusion.

Bunzl reports resilient first-quarter 2026 trading and reiterates full-year guidance

Bunzl said first-quarter revenue rose 1.5% at constant exchange rates, with underlying revenue up 2.0%, as volume growth and tariff-related price increases supported performance amid macroeconomic and geopolitical uncertainty.

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally well tolerated.

Search